Review article · 2023 · Open access
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Signal Transduction and Targeted Therapy, 8(1), 204 · Published 19 May 2023 · DOI 10.1038/s41392-023-01468-7
In brief
“Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer” is a 2023 review article by Xue Chen and 8 co-authors, published in Signal Transduction and Targeted Therapy. OpenAlex counts 871 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Signal Transduction and Targeted Therapy.
- Citations
- 871
- Most cited in
- 2026 (351)
- Field-weighted impact
- 19.52
- References
- 568
- Authors
- 9
Abstract
The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal transduction that enables cells to communicate with the exterior environment. Various cytokines, interferons, growth factors, and other specific molecules activate JAK-STAT signaling to drive a series of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy. Dysregulated JAK-STAT signaling and related genetic mutations are strongly associated with immune activation and cancer progression. Insights into the structures and functions of the JAK-STAT pathway have led to the development and approval of diverse drugs for the clinical treatment of diseases. Currently, drugs have been developed to mainly target the JAK-STAT pathway and are commonly divided into three subtypes: cytokine or receptor antibodies, JAK inhibitors, and STAT inhibitors. And novel agents also continue to be developed and tested in preclinical and clinical studies. The effectiveness and safety of each kind of drug also warrant further scientific trials before put into being clinical applications. Here, we review the current understanding of the fundamental composition and function of the JAK-STAT signaling pathway. We also discuss advancements in the understanding of JAK-STAT-related pathogenic mechanisms; targeted JAK-STAT therapies for various diseases, especially immune disorders, and cancers; newly developed JAK inhibitors; and current challenges and directions in the field.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Chen, X., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023). Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduction and Targeted Therapy, 8(1), 204. https://doi.org/10.1038/s41392-023-01468-7
MLA 9
Chen, Xue, et al. “Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.” Signal Transduction and Targeted Therapy, vol. 8, no. 1, 2023, p. 204. https://doi.org/10.1038/s41392-023-01468-7.
Chicago
Chen, Xue, Qinfan Yao, Xinyu Gu, Qingmiao Shi, Xin Yuan, Qingfei Chu, Zhengyi Bao, Juan Lu, and Lanjuan Li. 2023. “Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.” Signal Transduction and Targeted Therapy 8 (1): 204. https://doi.org/10.1038/s41392-023-01468-7.
Harvard
Chen, X. et al. (2023) ‘Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer’, Signal Transduction and Targeted Therapy, 8(1), p. 204. doi:10.1038/s41392-023-01468-7.
IEEE
X. Chen et al., “Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer,” Signal Transduction and Targeted Therapy, vol. 8, no. 1, p. 204, 2023, doi: 10.1038/s41392-023-01468-7.
BibTeX
@article{chen2023evolving,
title = {{Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer}},
author = {Chen, Xue and Yao, Qinfan and Gu, Xinyu and Shi, Qingmiao and Yuan, Xin and Chu, Qingfei and Bao, Zhengyi and Lu, Juan and Li, Lanjuan},
journal = {Signal Transduction and Targeted Therapy},
year = {2023},
volume = {8},
number = {1},
pages = {204},
doi = {10.1038/s41392-023-01468-7},
url = {https://doi.org/10.1038/s41392-023-01468-7}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2016 | 1 | |
| 2023 | 21 | |
| 2024 | 148 | |
| 2025 | 348 | |
| 2026 | 351 |
Its field-weighted citation impact is 19.52: it has been cited 19.52 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- JAK/STAT signaling
- Janus kinase
- signal transducer and activator of transcription
- cytokine signaling
- interferon
- autoimmune disease
- cancer
- JAK inhibitors
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Chen, X., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023). Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduction and Targeted Therapy, 8(1), 204. https://doi.org/10.1038/s41392-023-01468-7
How many times has this paper been cited?
871 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Signal Transduction and Targeted Therapy: sign in and open the PDF from this page.
Who wrote this paper?
Xue Chen, Qinfan Yao, Xinyu Gu, Qingmiao Shi, Xin Yuan, Qingfei Chu, Zhengyi Bao, Juan Lu, Lanjuan Li.
What is the DOI of this paper?
10.1038/s41392-023-01468-7, permanently at https://doi.org/10.1038/s41392-023-01468-7. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.